CA2502668C - Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain - Google Patents

Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain Download PDF

Info

Publication number
CA2502668C
CA2502668C CA2502668A CA2502668A CA2502668C CA 2502668 C CA2502668 C CA 2502668C CA 2502668 A CA2502668 A CA 2502668A CA 2502668 A CA2502668 A CA 2502668A CA 2502668 C CA2502668 C CA 2502668C
Authority
CA
Canada
Prior art keywords
ser
seq
amino acid
acid sequence
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2502668A
Other languages
English (en)
Other versions
CA2502668A1 (fr
Inventor
Rajendra V. Deshpande
Mei-Mei Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority claimed from PCT/US2002/033556 external-priority patent/WO2004046306A2/fr
Publication of CA2502668A1 publication Critical patent/CA2502668A1/fr
Application granted granted Critical
Publication of CA2502668C publication Critical patent/CA2502668C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des agents de liaison sélectifs de l'interféron-gamma (IFN.UPSILON.). L'invention concerne plus particulièrement des antigènes et des domaines de liaison d'antigènes se liant sélectivement à IFN.UPSILON. et pouvant être utilisés dans la prévention ou le traitement de troubles associés à des maladies auto-immunes ou inflammatoires telles que l'arthrite rhumatoïde, le lupus érythémateux systémique et la sclérose en plaques. L'invention concerne également des molécules d'acides nucléiques codant de tels anticorps et domaines de liaison d'antigènes, ainsi que des vecteurs d'expression et des cellules hôtes destinés à la production desdites molécules.
CA2502668A 2002-10-17 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain Expired - Fee Related CA2502668C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/033556 WO2004046306A2 (fr) 2001-10-05 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Publications (2)

Publication Number Publication Date
CA2502668A1 CA2502668A1 (fr) 2004-06-03
CA2502668C true CA2502668C (fr) 2013-07-30

Family

ID=34374685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2502668A Expired - Fee Related CA2502668C (fr) 2002-10-17 2002-10-17 Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain

Country Status (5)

Country Link
EP (1) EP1560595A4 (fr)
JP (1) JP2006502739A (fr)
AU (1) AU2002347978B2 (fr)
CA (1) CA2502668C (fr)
MX (1) MXPA05003949A (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体

Also Published As

Publication number Publication date
MXPA05003949A (es) 2005-06-17
JP2006502739A (ja) 2006-01-26
AU2002347978A1 (en) 2004-06-15
EP1560595A4 (fr) 2005-12-28
AU2002347978B2 (en) 2009-10-08
CA2502668A1 (fr) 2004-06-03
EP1560595A2 (fr) 2005-08-10

Similar Documents

Publication Publication Date Title
US7084257B2 (en) Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
DK2305715T3 (en) Monoclonal antibody to osteoprotegerin binding protein
US20050084493A1 (en) Screening method for antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
EP1257648B2 (fr) Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine
CA2502668C (fr) Fragments fab d'anticorps entierement humains ayant une activite de neutralisation de l'interferon-gamma humain
AU2001238680B2 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
DE DK et al. ANTAGONISTISCHE SELEKTIVE BINDUNGSAGENZIEN DES OSTEOPROTEGERIN-BINDUNGSPROTEINS AGENTS DE LIAISON SELECTIFS ANTAGONISTES DE PROTEINE DE LIAISON D’OSTEOPROTEGERINE
DE DK et al. Thousand Oaks, CA 91320-1799 (US)
DE DK et al. Designated Extension States
HK1158696B (en) Antagonistic selective binding agents of osteoprotegerin binding protein
HK1136308A (en) Antagonistic selective binding agents of osteoprotegerin binding protein
HK1136308B (en) Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001238680A1 (en) Antagonistic selective binding agents of osteoprotegerin binding protein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151019